A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Titel:
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Auteur:
Verstovsek, Srdan Mesa, Ruben A. Salama, Mohamed E. Li, Li Pitou, Celine Nunes, Fabio P. Price, Gregory L. Giles, Jennifer L. D’Souza, Deborah N. Walgren, Richard A. Prchal, Josef T.